APA (7th ed.) Citation

Orenstein, R., Hecht, G., Harvey, A., Tillotson, G., & Khanna, S. (2023). Two-year durability of REBYOTA™ (RBL), a live biotherapeutic for the prevention of recurrent Clostridioides difficile infections. Open Forum Infectious Diseases, 10(9), 1. https://doi.org/10.1093/ofid/ofad456

Chicago Style (17th ed.) Citation

Orenstein, Robert, Gail Hecht, Adam Harvey, Glenn Tillotson, and Sahil Khanna. "Two-year Durability of REBYOTA™ (RBL), a Live Biotherapeutic for the Prevention of Recurrent Clostridioides Difficile Infections." Open Forum Infectious Diseases 10, no. 9 (2023): 1. https://doi.org/10.1093/ofid/ofad456.

MLA (9th ed.) Citation

Orenstein, Robert, et al. "Two-year Durability of REBYOTA™ (RBL), a Live Biotherapeutic for the Prevention of Recurrent Clostridioides Difficile Infections." Open Forum Infectious Diseases, vol. 10, no. 9, 2023, p. 1, https://doi.org/10.1093/ofid/ofad456.